IBI188

A Phase 1b Study Evaluating the Safety and Efficacy of IBI188 in Combination With Azacitidine in Subjects With Newly Diagnosed Higher Risk Myelodysplastic Syndrome (MDS)

More Information

Trial Status
Not currently accepting
Trial Phase
Phase 1
Enrollment
32 patients (estimated)
Sponsors
Innovent Biologics (Suzhou) Co. Ltd.
Tags
Monoclonal Antibody, CD47
Trial Type
Treatment
Last Update
1 month ago
SparkCures ID
1370
NCT Identifier
NCT04511975

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.